AUA 2024: Dr. Zorn recaps key BPH research

In this video, Kevin C. Zorn, MD, FRCSC, FACS, recaps data in benign prostatic hyperplasia (BPH) that was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Zorn is the founder and director of BPH Canada in Montreal.

The following research is discussed:

1. P2-13: Preliminary RCT Analysis of Minimally Invasive Surgery vs. Medication in the Initial Treatment of BPH-Associated LUTS

2. MP27-04: Multi-center report on acute clinical outcomes with Rivermark FloStent™

3. MP20-02: Aquablation at 4-years: the largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

4. MP46-03: Preservation of Sexual Function with Optilume: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

5. MP20-05: Day Case Aquablation: First Published Experience Report in Ambulatory Surgical Center (ASC)